News

For the quarter ended March 2024, Gilead Sciences (GILD) reported revenue of $6.69 billion, up 5.3% over the same period last year. EPS came in at -$1.32, compared to $1.37 in the year-ago quarter.

The reported revenue represents a surprise of +5.59% over the Zacks Consensus Estimate of $6.33 billion. With the consensus EPS estimate being -$1.49, the EPS surprise was +11.41%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Product Sales- AmBisome- U.S. $14 million versus the four-analyst average estimate of $5.91 million. The reported number represents a year-over-year change of +133.3%.
• Product Sales- Vemlidy- U.S: $95 million versus the four-analyst average estimate of $88.09 million. The reported number represents a year-over-year change of +9.2%.
• Product Sales- Descovy- U.S: $371 million compared to the $415.49 million average estimate based on four analysts. The reported number represents a change of -6.1% year over year.
• Product Sales- Trodelvy- U. S: $206 million versus the four-analyst average estimate of $232.42 million. The reported number represents a year-over-year change of +27.2%.
• Product Sales- Yescarta- Total: $380 million compared to the $373.08 million average estimate based on nine analysts. The reported number represents a change of +5.9% year over year.
• Product Sales- Biktarvy- Total: $2.95 billion versus the nine-analyst average estimate of $2.88 billion. The reported number represents a year-over-year change of +10.1%.
• Product Sales- Trodelvy- Total: $309 million versus the nine-analyst average estimate of $323.02 million. The reported number represents a year-over-year change of +39.2%.
• Revenues- Royalty contract and other revenues: $39 million versus the nine-analyst average estimate of $51.89 million. The reported number represents a year-over-year change of -15.2%.
• Revenues- Product sales: $6.65 billion versus $6.30 billion estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +5.4% change.
• Product Sales- Tecartus- Total: $100 million versus the nine-analyst average estimate of $100.97 million. The reported number represents a year-over-year change of +12.4%.
• Product Sales- Total HIV: $4.34 billion versus $4.31 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +3.6% change.
• Product Sales- Odefsey- Total: $310 million versus $294.67 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -2.2% change.

View all Key Company Metrics for Gilead here>>>

Shares of Gilead have returned -8.1% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Free – 5 Dividend Stocks to Fund Your Retirement

Zacks Investment Research has released a Special Report to help you prepare for retirement with 5 diverse stocks that pay whopping dividends. They cut across property management, upscale outlets, financial institutions, and a couple of strong energy producers.

5 Dividend Stocks to Include in Your Retirement Strategy is packed with unconventional wisdom and insights you won’t get from your neighborhood financial planner.

Download Now – Today It’s FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.